Top Page
HBM Holdings Ltd.
(2142)
HBM Holdings Ltd. (2142) vs. S&P 500 (SPY)
HBM Holdings Ltd. Business Overview & Revenue Model
HBM Holdings Ltd. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 38.10M | 89.50M | 40.66M | 4.31M | 14.11M | Gross Profit |
| 33.61M | 87.47M | 40.53M | 4.17M | 13.66M | EBIT |
| -3.69M | 21.83M | -123.53M | -137.84M | -296.54M | EBITDA |
| -896.00K | 31.18M | -115.50M | -130.84M | -290.91M | Net Income Common Stockholders |
| 2.78M | 22.80M | -137.27M | -137.88M | -296.54M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 167.22M | 140.72M | 171.71M | 216.30M | 356.95M | Total Assets |
| 215.01M | 228.48M | 232.12M | 282.36M | 388.74M | Total Debt |
| 61.34M | 66.01M | 90.93M | 19.47M | 1.73M | Net Debt |
| -105.48M | -74.31M | -80.78M | -196.83M | -355.07M | Total Liabilities |
| 90.96M | 108.85M | 139.62M | 59.45M | 27.73M | Stockholders Equity |
| 124.45M | 119.99M | 92.83M | 223.19M | 361.19M |
| Cash Flow | Free Cash Flow | |||
| 30.44M | -21.60M | -118.40M | -139.81M | -35.99M | Operating Cash Flow |
| 30.68M | -19.12M | -99.96M | -125.61M | -35.39M | Investing Cash Flow |
| 6.55M | 28.09M | 137.59M | -76.90M | -93.53M | Financing Cash Flow |
| -10.24M | -29.14M | 70.58M | 1.59M | 357.86M |
HBM Holdings Ltd. Technical Analysis
HBM Holdings Ltd. Peers Comparison
HBM Holdings Ltd. Corporate Events
HBM Holdings Ltd. announced the grant of 4,875,000 share options to two non-connected employees under its Share Option Scheme. The options, priced at HK$8.60 per share, come with a 10-year exercise period and vesting conditions tied to individual performance appraisals. This initiative aims to incentivize employees to enhance the company’s value, aligning their interests with those of shareholders.
HBM Holdings Ltd. has issued a clarification regarding an error in the English version of its proxy form for the upcoming annual general meeting on June 11, 2025. The error involved the re-election of Dr. Xiaoping Ye as an independent non-executive director. The company has released a revised proxy form to ensure shareholders can vote accurately on this resolution. This announcement aims to maintain transparency and ensure proper governance practices, highlighting the company’s commitment to its shareholders.
HBM Holdings Limited has announced its upcoming annual general meeting, scheduled to take place on June 11, 2025, in Shanghai, China. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements for 2024, the re-election of two independent non-executive directors, and the re-appointment of Ernst & Young as the company’s auditor. Additionally, the board will seek authorization to issue new shares and fix directors’ remuneration, which could impact the company’s capital structure and governance.
HBM Holdings Ltd. has announced a plan to repurchase up to HK$200 million worth of its shares in the open market, as part of its ongoing strategy to enhance shareholder value. The company believes its current trading price undervalues its intrinsic worth and aims to demonstrate confidence in its business prospects through this initiative, while maintaining a solid financial position.
HBM Holdings Ltd. has successfully completed the issuance of 76,271,762 subscription shares to AstraZeneca Holdings under a general mandate, raising approximately US$105.3 million in gross proceeds. The net proceeds will be primarily used for pre-clinical discovery and research and development, with a portion allocated for working capital and general corporate purposes, positioning the company for future growth and development in the biotechnology sector.
HBM Holdings Ltd. announced its annual results for 2024, highlighting a significant decrease in revenue from $89.5 million in 2023 to $38.1 million in 2024, alongside a reduction in research and development expenses. The company reported a profit of $2.7 million for the year. Key business developments include the acceptance of a Biologics License Application for Batoclimab in China, the approval of an IND application for HBM9378 for COPD, and ongoing clinical trials for other products, indicating a strategic focus on advancing its therapeutic pipeline.
HBM Holdings Ltd. has announced a strategic collaboration with AstraZeneca, which includes a share subscription agreement and a partnership to develop next-generation multi-specific antibodies. The agreement will see AstraZeneca subscribe to 9.15% of HBM’s shares, raising approximately US$105.3 million for HBM’s research and development and operational needs. The collaboration is expected to enhance HBM’s position in the biopharmaceutical industry by leveraging AstraZeneca’s global drug development expertise, potentially leading to significant advancements in antibody therapeutics. This partnership also involves establishing an innovation center in Beijing and could result in up to US$4.4 billion in milestone payments for HBM, underscoring the potential impact on the company’s growth and market presence.
HBM Holdings Limited has announced that its board of directors will meet on March 31, 2025, to consider and approve the annual results for the year ending December 31, 2024. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and strategic direction.
HBM Holdings Ltd. announced that it has received an upfront payment from Windward Bio AG as part of an exclusive license agreement for HBM9378/SKB378. This payment, which includes both cash and equity interest, is expected to strengthen the company’s cash reserves, potentially enhancing its operational capabilities and market positioning.
HBM Holdings Limited announced a license and collaboration agreement through its subsidiary, HBM Alpha Therapeutics, with a business partner to develop therapies targeting corticotropin-releasing hormone (CRH) for various disorders. The agreement grants the partner exclusive worldwide rights, excluding Greater China, to exploit pharmaceutical products containing HBM9013, with potential payments to HBMAT totaling up to $395 million and additional royalties. This collaboration could enhance HBM Holdings’ position in the biotechnology industry by addressing unmet medical needs in CRH-related disorders, potentially impacting stakeholders positively.
HBM Holdings Ltd. has reported strong business performance for the year ended December 31, 2024, with expected profits ranging from RMB7.3 million to RMB22 million, and a cash profit reaching a historical high of RMB220 million. This success is attributed to strategic partnerships, growing recurring revenue, and efficient cost management. The company has repurchased shares worth nearly HK$30 million, reflecting confidence in its business outlook and indicating a perceived undervaluation of its shares.